Infigen Inc.

Infigen is a biotechnology company developing nuclear transfer and genomic technologies for applications in human healthcare.

The company was spun off from American Breeders Service (ABS) Global in 1997; in 2001 the company received an NIH-SBIR award to develop embryo-based assays using cDNA microarrays in a porcine model.

The closure of the company was reported in 2004.

Walter A. Simson III, CEO
Kenneth J. Eilertsen, PhD, Director of Genomics and Molecular Biology
Erik J. Forsberg, PhD Vice President of Development
Daniel C. Paltz, Director of Finance

1825 Infinity Drive
DeForest, WI 53532
USA
Phone: +1-608-846-0500
Fax: +1-608- 846-0520

The company’s work is focused on four distinct platforms: 1) Therapeutic proteins involving transgenic and non-transgenic cloned animals as bioreactors. 2) Xenotransplantation involving miniaturized pigs as an alternative source of organs, etc. 3) Genomic reprogramming involving animal embryos with the purpose of finding new medicines and therapies. 4) Animal models of disease for studying human diseaes etiology involving genetically-modified pigs.

Infigen currently holds 69 issued patents as well as 41 pending patent applications. The key patents are listed below.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.